Pharming PHAR
NASDAQ PHAR
$10.60 +0.95 (+9.84%)
As of: Oct 22, 2026 · 10:38 AM EDT

Pharming (PHAR) Long-Term Debt Repayments (2020)

Updated

Analysis

Pharming (PHAR) Long-Term Debt Repayments (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,166.12 Bn 1,134.70 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 634.67 Bn 553.20 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn 2.00 Bn
4 Merck 377.66 Bn 332.04 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 303.82 Bn 267.81 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 266.80 Bn 240.49 Bn 12.86 Bn 2.46 Bn
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn -
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.20 Bn 118.84 Bn 10.94 Bn -
10 Pharming 730.10 Mn -64.27 Mn 141.47 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 119.23 Mn
API Access

Pharming Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=PHAR&period=max&api_key=YOUR_API_KEY